3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
6
Terminated
3
Active not recruiting
3
Unknown
2
Not yet recruiting
2
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Recurrence
1
Neoplasm, Residual
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Interventions
siremadlin
1
selinexor
1
posaconazole
1
midostaurin
1
fludarabine
1
durvalumab
1
blinatumomab
1
avelumab
1
Radiosurgery
1
Midazolam
1
Lenalidomide
1
Idarubicin
1
Dexamethasone
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Calcium Dobesilate
1
Azacitidine
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasm, Residual
×
blinatumomab
×
Clear all
NCT03982992
2024-03-12
DLI-TARGET
Ludwig-Maximilians - University of Munich
Phase 2
Withdrawn